🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to scientists.

A Global Health Concern

Cases of gonorrhoea are increasing worldwide, with figures suggesting in excess of 82 million instances per year. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the reality of rising global incidence, escalating drug resistance and the highly restricted available drugs currently available.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, also known as a brand name, was cleared by the US FDA in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in the same week. This medication, which is employed against UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to see it through.

“This authorization represents a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Outcomes and Worldwide Availability

According to data published in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves two antibiotics. The study included nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in many regions with limited resources.

Clinicians directly involved have expressed positive views. Access to a easy-to-administer therapy like this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to alleviate the strain of the disease for patients and to prevent the spread of untreatable gonorrhoea globally.